Product Description: Cadonilimab (AK104) is a targeting PD1/CTLA4 IgG1 scaffold Fc-engineered humanized antibody. Cadonilimab can be used for researching metastatic cervical cancer[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Antonarelli G, et al. Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals (Basel). 2021 Aug 31;14(9):884./[2]Kaplon H, et al. Antibodies to watch in 2022. MAbs. 2022 Jan-Dec;14(1):2014296.